Aska Pharmaceutical Company Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aska Pharmaceutical Company Limited
Private Company Edition: The Paragon Biosciences-founded Emalex previously raised $35m when ecopipam was in Phase II. Also, Catalio Capital launches a “special situations” fund, Zenas raises $118m to develop a pipeline of autoimmune disease treatments and Lusaris emerges with $60m.
Less than two year after going public by a SPAC merger, Gemini will reverse merge with hematology-focused Disc. Bristol Myers Squibb and GentiBio will join forces on Treg development for inflammatory bowel disorders.
Public Company Edition: William Blair analysts note that stock prices are rising due to a Q2 boost in dealmaking after a lull in Q1. Nevertheless, layoffs and portfolio prioritizations are ongoing, including at X4 Pharmaceuticals, but others have raised cash following good news, like Revolution Medicines.
Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.
- Medical Devices
- Generic Drugs
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools